SOX3 is located on the long arm o the chromosome 27.1 and both the nder-and o er-expression o this gene ha e been reported in cases o hypopit itarism with or witho t intellect al disabilities. e ertheless only a ew cases ha e as yet been extensi ely described. E IG : A -year 11 month-old male was bro ght in or growth ail re height -2.
INTRODUCTION
Pituitary gland development and function depend on the sequential temporal and spatial expression of multiple transcription factor genes, such as POU1F1 (POU class 1 homeobox 1; OMIM 173110), PROP1 [1] [2] [3] Congenital hypopituitarism (CH), a defect that is characterised by a deficiency in one or more pituitary hormones and is not rare, may be caused by mutations in any of these genes. 4 CH manifests either as an isolated hormone deficiency, the most common being isolated growth hormone deficiency (IGHD) or as multiple pituitary hormone involvement [combined pituitary hormone deficiencies (CPHD)]. [1] [2] [3] The CH clinical features may be detected in the neonatal period or present later in life. 4, 5 Moreover, hormonal deficits may be associated with extra-pituitary defects affecting organs that are embryologically correlated. 4, 5 SOX3 is a single exon gene located on the long arm of the X chromosome (Xq27.1). SOX3 is a member of the SOX (SRY-related high mobility group box) family of transcription factors that is expressed in neuroepithelial progenitor and stem cells beginning in the earliest stages of embryogenesis. 6, 7 Sox/SOX genes have been recognised as key players in the regulation of embryogenesis and nervous system development; they encode transcription factors that act as key regulators in different developmental processes, such as gastrulation, neural induction, specification, and the differentiation of many cell types. 8, 9 SOX3 has also been implicated in the aetiology of a septo-optic dysplasia variant. 3 The dysfunction of the SOX3 protein disturbs cellular processes that are required for cognitive and pituitary development. 10 In fact, in human males, both the under-and over-expression of this gene lead to CPHD or IGHD and infundibular hypoplasia, an ectopic/undescended posterior pituitary and abnormalities of the corpus callosum with or without intellectual disability (ID). [10] [11] [12] However, micro-duplications of SOX3 have been identified in only a few patients with IGHD or CPHD, 10, [13] [14] [15] [16] frequently accompanied by poor endocrinological 13, 15, 16 or clinical 10,13 data.
CASE REPORT
The propositus was the second child of young, healthy, non-consanguineous parents of Italian origin. The target height was normal [0.5 standard deviation score 9SDS)]. After a miscarriage, the couple had a son with normal growth and neuropsychological development (the pedigree is illustrated in Figure 1 ).
The patient was born by caesarean section for podalic presentation at term of the 3 rd uneventful pregnancy. The birth weight was 3.030 kg (0.1 SDS), the length was 52 cm (0.4 SDS) and the head circumference was 34.8 cm (-0.3 SDS). The Apgar score was 9 I -10 V . Genital abnormalities were not observed, nor were hypoglycaemias.
During the first year of life, a mild developmental delay became evident: he sat at 8 months and walked independently at 22 months, while language started at 24 months. Intellectual disability was ascertained at the age of 2 yr and 6 mo: the developmental quotient (DQ) was 65. In the same period, an ophthalmologic examination was carried out: the fundus and visual acuity were normal, but a gaze-evoked horizontal nystagmus and ocular saccadic overshot were observed, leading to a suspicion of a diagnosis of ocular dyspraxia.
At 3 yr and 11 mo old, due to pronounced growth failure (height -2.4 SDS), an endocrinological evaluation of the child was conducted which revealed a very low IGF-I concentration (44 μg/L). Bone age was considerably delayed (2 yr and 1 mo at 3 yr and 11 mo of chronological age). A growth hormone stimulation test disclosed a classic GH deficiency (GH peak after clonidine 2.4 ng/ mL; GH peak after arginine 2.1 ng/mL). An MRI revealed an anterior pituitary hypoplasia with ectopic neurohypophysis, corpus callosum hypogenesis, and incomplete myelination ( Figure 2 ). The posterior fossa was significantly reduced.
Based on these findings, rhGH treatment was conducted (0.23 mg/kg per week subcutaneously). The auxological follow-up showed a strong positive response to the treatment with the standard deviationgrowth velocity (SDS-GV) increasing remarkably during therapy (Figure 3 ).
At 9 yr and 9 mo, the height was 0.3 SDS, the weight was 0.1 SDS, and the pubertal evaluation was PH1 AH1 T2 ml bilaterally. Bone age remained considerably delayed (6 yr and 1 mo at 9 yr and 9 mo of chronological age). During follow-up, a periodic evaluation of the other adenohypophyseal hormones ig re 1. Pedigree of the family that was analysed in this study. Duplications were found in the proband and mother.
ig re 2. Sagittal MRI scan of the patient with SOX3 duplication, showing pituitary hypoplasia, hypoplasia of the infundibulum, and an undescended/ectopic posterior pituitary. Note the hypogenesis of the corpus callosum. disclosed deficiency. At 6 yr and 8 mo of age, the FT4 was 1.56 ng/dL, the TSH was 3.01 μUI/dL, the cortisol was 11.45 μg/dL, the ACTH was 42 ng/L and the PRL was 69 mUI/ml.
Due to the presence of neuromotor delays and MRI abnormalities, a genetic evaluation was carried out. The patient's DNA was analysed using array CGH (comparative genomic hybridisation). After obtaining informed consent, the genomic DNA was extracted from the leukocytes of the proband, i.e. both his parents and maternal grandparents according to standard procedures. Array CGH was performed using the Agilent 60k platform with a median resolution rate of nearly 100 kilobases (kb). Based on the physical mapping positions that were designated at the March 2006 assembly (NCBI36/ hg18) of the UCSC Genome Browser, this analysis showed a duplication that involved the Xq26.3-27.3 region with an extension between 135,175,703 bp (first duplicated) and 142,971,531 bp (last duplicated) ( Figure 4 ; Table 1 ): a 7.8 megabase (Mb) duplication was identified in Xq26.3 -27.3 spanning more than 20 genes, among which the morbid genes were ig re . Growth chart of the patient. The arrows indicate the age of onset for growth hormone treatment (black arrow).
ig re . Array-CGH analysis showing a duplication that included Xq26.3-27.3 with the extension between 135,175,703 bp (first duplicated) and 142,971,531 bp (last duplicated). 
DISCUSSION
We describe a new case of isolated GHD in a patient with the duplication Xq26.3-27.3 comprising the SOX3 gene. The growth failure was relatively severe, but a significant catch-up growth achieved after a long-term follow-up with rhGH treatment confirmed the diagnosis of GHD.
Additional pituitary deficiencies were not recorded, and an evaluation of a possible LH/FSH deficiency will be performed in the future.
GHD has been reported in most cases of SOX3 involvement (Tables 1 and 2) . 10, 13, 14, [17] [18] [19] Recently, Takagi described a male patient with Kabuki syndrome due to a mutation in KMT2D (Lysine-Specific Methyltransferase 2D). KMT2D is involved in the majority of cases of Kabuki syndrome, a condition that is sometimes associated with GHD. As the patient also had CPHD, the authors analysed all of the coding exons and flanking introns of currently known genes responsible for CPHD by PCR-based sequencing, discovering a mutation in SOX3 consisting of a deletion in the polyalanine (PA) tracts of SOX3. This study provides additional evidence that SOX3 mutations must be looked for in hypopituitarism.
As documented by Woods et al, the over-and under-expression of SOX3 is associated with significant interfamilial phenotypic variability, which may be seen in many patients even with identically sized expansions. 10 To the best of our knowledge, this case is the second described isolated case of GHD after the patient who was reported by Burkitt Wright. 18 In fact, GHD is more frequently associated with TSH deficiencies, the exceptions being the cases published by Hol, 14 Burkitt Wright, 18 and ourselves; ACTH 10, 13, 14, 19 or gonadotropin 10, 13, 17, 18 deficiencies have been more rarely diagnosed, even though in many cases specific diagnostic tests were not carried out. 16 Therefore, based on the evaluation of the various pituitary defects and molecular diagnoses (sequence variant and whole gene deletion or duplication), patients with duplication of SOX3 could present an IGHD without the involvement of additional adenohypophyseal hormones, 10,14,15 more frequently with respect to patients with SOX3 sequence variants. 10, 17, 19 Nevertheless, the cases that were reported by Hol et al 14 and Woods et al 10 with the duplication Xq26.3-27.3 also displayed in CPHD. Other subjects with SOX3 duplication that were described by Salomon et al 20 have not been confirmed. 21 Anterior pituitary hypoplasia, an absent stalk, and ectopic neurohypophysis are other useful findings that can support the diagnosis of CPHD or IGHD due to SOX3 sequence variants or whole gene deletions/ duplications. 22 However, some patients lack descriptions of their hypothalamic-pituitary anatomy, 10, [12] [13] [14] [15] whereas others disclosed only partially the MRI characteristics that have been described as typical of SOX3 involvement. For example, in a case that was described by Woods et al, 10 MRI abnormalities were absent, such as in the patient who was reported by Helle et al 23 and one of the patients who was reported by Hol et al. 14 Nevertheless, the case of Helle et al 23 showed hyperphagia, most likely with a hypothalamic origin without other typical SOX3 involvement characteristics; this patient did not have hypopituitarism.
Available evidence demonstrates that either the over-or under-expression of SOX3 can result in the perturbation of pituitary and hypothalamic development. 24 Altered SOX3 d osage may also be the causative mechanism for the X-linked hypopituitarism that is associated with infundibular hypoplasia, an ectopic/ undescended posterior pituitary, and abnormalities of the corpus callosum (with or without ID). 10, 12, 17, 19 Therefore, the presence of IGHD or CPHD in males, in particular if presenting ID, may be a useful indicator of potential defects in SOX3.
ID is frequently reported in these patients. The degree of mental retardation and the characteristics vary among patients. [12] [13] [14] [15] 23 Even though mental retardation is reported in the majority of patients with SOX3 duplications, 13-15 this trait was not present in the cases that were documented by Woods et al 10 , which were characterised by a smaller duplication (685.6 kb in length). Although one of these patients exhibited hyperactivity, the absence of ID in some patients 10, 17, 18 may result from different dosage effects.
Vertebrate embryonic stem cells express the Sox2 transcription factor, which, together with the closely related Sox1 and Sox3 proteins, forms the SoxB1 subgroup of the Sox protein family. First, Bergsland et al found that the genome-wide binding patterns of Sox2 and Sox3 in neural precursor cells (NPCs) overlap extensively, with 96% of the Sox2-bound sites also bound by Sox3. 25 Therefore, a substantial number of the identified binding sites are part of brain-specific regulatory regions. Both high and low levels of Sox3 can deleteriously affect normal brain function and physiology. In fact, constitutively active Sox3 leads to increased apoptosis. 26 In conclusion, IGHD and CPHD are frequently reported characteristics in patients with SOX3 involvement. The association with mental retardation is also typically present, more frequently in SOX3 duplication than in mutations. In the case of males with mental retardation and postnatal growth failure due to IGHD or associated with CHPD, the involvement of SOX3 may be considered.
